3-(1H-pyrrol-2-yl)-1H-pyrazole | 1253645-55-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯
• 英文名称: 3-(1H-pyrrol-2-yl)-1H-pyrazole
• 英文别名: 5-(1H-pyrrol-2-yl)-1H-pyrazole
• CAS: 1253645-55-4
• 化学式: C₇H₇N₃
• mdl: MFCD06808816
• 分子量: 133.153
• InChiKey: FYVOJZAKVSEZOA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  44.5
• 氢给体数：
  2
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  (E)-3-(dimethylamino)-1-(1H-pyrrol-2-yl)prop-2-en-1-one 在 一水合肼 作用下， 105.0~110.0 ℃ 、101.33 kPa 条件下， 反应 0.12h， 生成 3-(1H-pyrrol-2-yl)-1H-pyrazole
  参考文献：
  名称：

  Saleh; Elkholy; Mohamed, Egyptian Journal of Chemistry, 2009, vol. 52, # 2, p. 277 - 288

  摘要：

  DOI：

文献信息

• Adamantyl-pyrazole carboxamides as inhibitors of 11B-hydroxysteroid dehydrogenase
  申请人：Anderson Kevin William

  公开号：US20070225280A1

  公开（公告）日：2007-09-27

  Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, type II diabetes mellitus and metabolic syndrome.

  本文提供了以下式（I）的化合物： 以及其药学上可接受的盐，其中取代基如规范中所披露的那样。这些化合物及含有它们的药物组合物对于治疗诸如II型糖尿病和代谢综合征等疾病是有用的。
• NON-ATP DEPENDENT INHIBITORS OF EXTRACELLULAR SIGNAL-REGULATED KINASE (ERK)
  申请人：Shapiro Paul S.

  公开号：US20140179743A1

  公开（公告）日：2014-06-26

  A compound, having the formula A-1: Wherein R 1 and R 2 are defined herein. Methods of using the compound and compositions containing the compound are provided.

  一个具有化学式A-1的化合物，其中R1和R2在此处被定义。提供了使用该化合物的方法和含有该化合物的组合物。
• Pyrazoles
  申请人：Gillespie Paul

  公开号：US20060223852A1

  公开（公告）日：2006-10-05

  Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, type II diabetes mellitus and metabolic syndrome.

  本文提供了公式（I）的化合物，以及其药学上可接受的盐，其中取代基如规范中所披露的那样。这些化合物及含有它们的药物组合物对于治疗疾病，例如II型糖尿病和代谢综合征等，具有用处。
• Microcin B17 Analogs And Methods For Their Preparation And Use
  申请人：Coquin Laurence

  公开号：US20080234132A1

  公开（公告）日：2008-09-25

  The present invention pertains to synthetic analogues of microcin B17 component units, methods of making and using these analogues, including, for example, as inhibitors of DNA gyrase. More particularly, the present invention pertains to compounds of the Formula wherein: W is independently: —H or a peptide group; Z is independently: —OH or a peptide group; wherein each peptide group, if present, is: an amino acid group and comprises exactly one amino acid, or: a poly(amino acid) group and comprises two or more amino acids; R N3 is independently: —H, C 1-6 alkyl, C 2-6 alkenyl, C 3-6 cycloalkyl, or C 3-6 cycloalkenyl, C 6-14 -carboaryl, C 5-14 heteroaryl, C 6-14 carboaryl-C 1-6 alkyl, C 5-14 heteroaryl-C 1-6 alkyl, and is optionally substituted; the circle represents a mono-heterocycle or a bis-heterocycle, wherein the heterocycle, or each of the two heterocycles, is a five membered ring having at least a first ring heteroatom that is N, and optionally a second ring heteroatom that is selected from N, O, and S; and the heterocycle, or each of the two heterocycles, is optionally substituted with one or more substituents; and pharmaceutically acceptable salts, amides, esters, solvates, and hydrates thereof. The present invention also pertains to uses of such compounds, for example, to inhibit DNA Gyrase activity in a cell and in methods of therapy, for example, to treat a disease or condition that is ameliorated by the inhibition of DNA Gyrase, such as a bacterial infection, cancer, etc.; as a herbicide; as a microbicide; as a bactericide; etc.

  本发明涉及微小肽B17组分单元的合成类似物，制备和使用这些类似物的方法，包括作为DNA酶抑制剂。更具体地说，本发明涉及以下式的化合物：其中：W独立地为：—H或肽基团；Z独立地为：—OH或肽基团；其中每个肽基团，如果存在，则为：氨基酸基团，包括恰好一个氨基酸，或：多肽（氨基酸）基团，包括两个或更多氨基酸；RN3独立地为：—H、C1-6烷基、C2-6烯基、C3-6环烷基或C3-6环烯基、C6-14芳基、C5-14杂芳基、C6-14芳基-C1-6烷基、C5-14杂芳基-C1-6烷基，并且可选地被取代；圆圈表示单杂环或双杂环，其中杂环或两个杂环中的每一个都是具有至少一个第一环杂原子的五元环，该原子是N，可选地，第二环杂原子是从N、O和S中选择的；并且该杂环或两个杂环可选地被一个或多个取代基取代；以及其药学上可接受的盐、酰胺、酯、溶剂化物和水合物。本发明还涉及这些化合物的用途，例如，在细胞中抑制DNA酶活性和治疗方法中使用，例如治疗通过抑制DNA酶改善的疾病或病况，如细菌感染、癌症等；作为除草剂；作为杀菌剂；作为杀菌剂等。
• Pyrazoles as 11-beta-hsd-1
  申请人：F. Hoffmann-La Roche AG

  公开号：EP2295411A1

  公开（公告）日：2011-03-16

  Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, type II diabetes mellitus and metabolic syndrome.

  本文提供的是式 (I) 的化合物： 及其药学上可接受的盐类，其中的取代基与说明书中公开的取代基相同。这些化合物以及含有它们的药物组合物可用于治疗诸如 II 型糖尿病和代谢综合征等疾病。